Polypharmacy

Polypharmacy has been studied in 470 papers since 2015: 5 trials and 395 observational studies in people, 10 in animals, 60 reviews; 147 in the past year. The newest story, Nov 6, 2026: “Some older women may gain little from breast cancer hormone therapy”.

Exposure

470 papers study it445 findingsUpdated

MeSH

Research on it is growing 43% faster than aging research as a whole: 72 papers in the latest year counted

21 new papers in 30 daysSee all 470 papers on polypharmacy

At a glance

Independent labs found the same change in people. 230 independent labs in 50 countries; 1 trial, none about aging, 1 with no results posted.

“Incidence of all-cause hospitalization, and heart failure hospitalization or cardiovascular death increased with higher medication burden”
Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trialNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2026doi:10.1093/ndt/gfag203

36 of its findings point the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 230 independent labs in 50 countries
  • 36 findings against
  • 1 trial, none about aging, 1 with no results posted
  • Funders: National Institutes of Health and others
  • 25 of 421 findings with company ties
  • Human trial5
  • Humans395
  • Animals10

What did studies of polypharmacy find?

60

Studies of polypharmacy measured 60 outcomes; the most studied are physical function (8 studies), cognitive function (7) and frailty (6).

Physical function

downin humans6downin mice2OR 4

8 studies
  1. Polypharmacy is linked with worse physical function in humans.

    “Polypharmacy, low muscle mass, and lower educational levels were associated with poorer physical performance.”

    Humansn = 445

    The Association between Polypharmacy, Low Appendicular Skeletal Muscle Mass Index, and Physical Performance: A Cross-Sectional Study

    Gerontology

  2. Polypharmacy is linked with worse physical function in humans (community-dwelling older adults).

    “In both age groups, a higher number of medications was associated with lower Barthel Index, EQ-5D and EQ-VAS scores”

    Humanscommunity-dwelling older adultsn = 384

    Quality of life, grip strength, health indicators, and clinical risk in older adults: A cross-sectional study

    Geriatric nursing (New York, N.Y.)

  3. Polypharmacy is linked with worse physical function in humans (-1.24 points (95% CI -1.58, -0.90)).

    “Estimated CAPP score was 1.24 points lower among participants with polypharmacy vs. no polypharmacy (95% confidence interval [95%CI] -1.58, -0.90; p < 0.001).”

    Humansn = 1,842

    Association Between Polypharmacy and Physical Function in Middle-aged Adults: Findings from the CARDIA Function Study

    Journal of general internal medicine

  4. Polypharmacy is linked with worse physical function in older adults with ADRD.

    “Older adults with both ADRD and PPY had lower physical function”

    Humansin older adults with ADRDn = 2,052

    Impact of Polypharmacy on Symptoms and Health Outcomes in Older Adults With and Without Alzheimer's Disease and Related Dementias

    Biological research for nursing

  5. Polypharmacy is linked with worse physical function in humans (cancer) (OR 4.0, 95% CI 1.59-10.06).

    “Polypharmacy was associated with the four time the risk of functional impairment in middle-aged (OR 4.0, 95% CI 1.59-10.06) and older individuals (OR 4.4, 95% CI 1.6-11.7).”

    Humanscancer5 years

    Impact of comorbidities on physical function and survival of middle-aged, as compared to older, individuals with cancer

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

  6. Polypharmacy impairs physical function in older adults.

    “polypharmacy is associated with impaired physical function”

    Reviewin older adults

    POLYPHARMACY: TRANSLATIONAL RESEARCH TO UNDERSTAND EFFECTS OF AGE, SEX, AND FRAILTY ON KEY OUTCOMES FOR FORTITUDE

    GSA 2024 abstract

  7. Polypharmacy decreases physical function in mice (compared with control, in both ages and sexes) (p < .001).

    “Compared to control, polypharmacy reduced physical function (grip strength, rotarod latency, gait speed, and total distance)”

    Animalscompared with control, in both ages and sexes4-6 weeks

    Polypharmacy Results in Functional Impairment in Mice: Novel Insights Into Age and Sex Interactions

    The journals of gerontology. Series A, Biological sciences and medical sciences

  8. Polypharmacy impairs physical function in mice (increasing Drug Burden Index).

    “Polypharmacy with increasing DBI and monotherapy with citalopram caused mice to become frailer, less mobile, and impaired their strength and functional activities.”

    Animalsincreasing Drug Burden Indexmales

    Chronic Polypharmacy with Increasing Drug Burden Index Exacerbates Frailty and Impairs Physical Function, with Effects Attenuated by Deprescribing, in Aged Mice

    The journals of gerontology. Series A, Biological sciences and medical sciences

Cognitive function

no changein humans4downin humans3

7 studies
  1. Polypharmacy was not clearly linked with cognitive function in humans (African American adults; adjusted for modified Charlson Comorbidity Index) (B = -0.081; β = -0.057; p = 0.257).

    “Polypharmacy was not independently associated with cognition after modified CCI adjustment (B = -0.081; β = -0.057; p = 0.257).”

    HumansAfrican American adults; adjusted for modified Charlson Comorbidity Index≥5 medications73.6% femalesn = 348

    Multimorbidity, Polypharmacy, and Neighborhood Disadvantage as Determinants of Cognitive Performance in the ARCHES Cohort

    Journal of applied gerontology : the official journal of the Southern Gerontological Society

  2. Polypharmacy is linked with worse cognitive function in humans (heart failure outpatients) (ρ=0.276, p=0.004).

    “Cognitive category correlated with polypharmacy (ρ=0.276; p=0.004)”

    Humansheart failure outpatientsn = 107

    Polypharmacy and Potentially Inappropriate Medications: Cognitive Consequences in Older Heart Failure Outpatients

    Romanian journal of internal medicine = Revue roumaine de medecine interne

  3. Polypharmacy is linked with worse cognitive function in humans (β = −0.03, 95% CI −0.05 to −0.01).

    “a significant interaction between time and medication count was observed [β = −0.03, 95% credible interval (CI) − 0.05 to −0.01]”

    Humans10-year follow-upn = 843

    Association of polypharmacy with cognitive decline and mortality in the oldest old: findings from the Newcastle 85+ study

    Research Connections

  4. Polypharmacy was not clearly linked with cognitive function in humans after adjustment.

    “In this population, polypharmacy was not associated with cognitive screening outcomes”

    Humansafter adjustmentn = 848

    Prevalence and determinants of polypharmacy and its association with cognitive and functional performance in community-dwelling older adults: A population-based study

    Journal of Alzheimer's disease : JAD

  5. Polypharmacy was not clearly linked with cognitive function in humans (p = 0.910).

    “No statistically significant differences were found between the groups in terms of cognitive function (p = 0.910)”

    Humansn = 164

    Multidimensional Impact of Polypharmacy on Cognitive Function, Depression, Functionality, and Quality of Life in Older Adults: A Cross-Sectional Study

    İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi

  6. Polypharmacy is linked with lower cognitive function in humans (taking ≥8 medications at discharge) (median: 23 vs 32; r = -0.384, P = .016).

    “In the 75-89 years age group, polypharmacy defined as taking ≥8 medications at discharge was significantly associated with lower cognitive FIM scores (median: 23 vs 32; r = -0.384, P = .016).”

    Humanstaking ≥8 medications at dischargen = 86

    Relationship between polypharmacy and activities of daily living or in-hospital falls in elderly patients hospitalized for proximal femoral fracture: A retrospective cohort study

    Medicine

  7. Polypharmacy was not clearly linked with cognitive function in humans (women with HIV).

    “Moderate polypharmacy was not associated with cognition.”

    Humanswomen with HIV5-9 non-ART medicationsmedication use in the prior 6 monthsfemales

    Degree of Polypharmacy and Cognitive Function in Older Women with HIV

    AIDS research and human retroviruses

Frailty

upin humans4no changein humans1upin mice1

6 studies
  1. Polypharmacy is linked with higher frailty in humans (community-dwelling) (p < 0.05).

    “Older adults with polypharmacy had higher levels of frailty and lower quality of life”

    Humanscommunity-dwellingn = 120

    Examining the Effect of Polypharmacy on Quality of Life and Frailty in Older Adults from the Perspective of Community-Based Rehabilitation

    Healthcare (Basel, Switzerland)

  2. Polypharmacy was not clearly linked with frailty in humans (uninfected) (not statistically significant).

    “not statistically significant among the uninfected”

    Humansuninfectedn = 132

    Correlation Between Polypharmacy and Frailty Among Thai Older Persons Living with HIV

    AIDS research and human retroviruses

  3. Polypharmacy increases frailty in humans.

    “polypharmacy may worsen frailty”

    Review

    The significance of frailty in the assessment of polypharmacy and deprescribing

    Ugeskrift for laeger

  4. Polypharmacy increases frailty in older adults, particularly women.

    “polypharmacy is associated with impaired physical function and exacerbates frailty in older adults”

    Reviewin older adults, particularly women

    POLYPHARMACY: TRANSLATIONAL RESEARCH TO UNDERSTAND EFFECTS OF AGE, SEX, AND FRAILTY ON KEY OUTCOMES FOR FORTITUDE

    GSA 2024 abstract

  5. Polypharmacy increases frailty in humans.

    “Polypharmacy is an important factor causing the progression of frailty in geriatric syndrome.”

    Review

    Similarities, differences and overlaps between frailty and Parkinson's disease

    Geriatrics & gerontology international

  6. Polypharmacy increases frailty in mice (increasing Drug Burden Index).

    “Polypharmacy with increasing DBI and monotherapy with citalopram caused mice to become frailer, less mobile, and impaired their strength and functional activities.”

    Animalsincreasing Drug Burden Indexmales

    Chronic Polypharmacy with Increasing Drug Burden Index Exacerbates Frailty and Impairs Physical Function, with Effects Attenuated by Deprescribing, in Aged Mice

    The journals of gerontology. Series A, Biological sciences and medical sciences

Mortality

no changein humans4upin humans1HR 1.02–1.05

5 studies
  1. Polypharmacy was not clearly linked with mortality in humans (HR = 1.02, 95% CI 0.97–1.07).

    “medication count was not significantly associated with mortality (hazard ratio, HR = 1.02, 95% CI 0.97–1.07)”

    Humans10-year follow-upn = 843

    Association of polypharmacy with cognitive decline and mortality in the oldest old: findings from the Newcastle 85+ study

    Research Connections

  2. Polypharmacy was not clearly linked with mortality in humans (emergency laparotomy).

    “There was no significant difference in mortality up to 1 year following surgery between those with or without polypharmacy, nor those with or without significant ACB.”

    Humansemergency laparotomyn = 144

    Polypharmacy and anticholinergic burden are common but not independently associated with outcomes after emergency laparotomy in older adults

    Langenbeck's archives of surgery

  3. Polypharmacy is linked with higher mortality in humans (non-valvular atrial fibrillation) (P<0.05).

    “all-cause death significantly increased (each, P<0.05). In multivariate analysis, increasing medications was independently associated with increases in these events”

    Humansnon-valvular atrial fibrillation24-monthn = 31,419

    Effect of Polypharmacy on Clinical Outcomes in Elderly Patients With Non-Valvular Atrial Fibrillation - A Sub-Analysis of the ANAFIE Registry

    Circulation journal : official journal of the Japanese Circulation Society

  4. Polypharmacy was not clearly linked with mortality in humans (newly admitted nursing home residents).

    “Neither polypharmacy nor PIM use at admission were associated with mortality.”

    Humansnewly admitted nursing home residentsfour yearsn = 613

    Associations of potentially inappropriate medication use with four year survival of an inception cohort of nursing home residents

    Archives of gerontology and geriatrics

  5. Polypharmacy showed no clear effect on mortality in humans (patients with heart failure) (HR 1.05, 95% CI 0.88–1.25).

    “No significant associations were found for CV death (HR: 1.07; 95% CI: 0.81-1.41) or all-cause mortality (HR: 1.05; 95% CI: 0.88-1.25).”

    Reviewpatients with heart failure

    Cardiovascular risk associated with polypharmacy in heart failure: a systematic review and meta-analysis

    ESC heart failure

Sarcopenia

no changein humans3

3 studies
  1. Polypharmacy was not clearly linked with sarcopenia in humans (hospitalized patients) (87.8% vs 80.6%).

    “Polypharmacy was not independently associated with sarcopenia in hospitalized older adults.”

    Humanshospitalized patientsn = 206

    Relationship between polypharmacy, sarcopenia and drug classes in hospitalized older patients

    Aging clinical and experimental research

  2. Polypharmacy was not clearly linked with sarcopenia in patients on hemodialysis.

    “whereas no significant associations were observed with sarcopenia.”

    Humansin patients on hemodialysis

    Polypharmacy and sarcopenia in patients on hemodialysis: results from the SARC-HD study

    Aging clinical and experimental research

  3. Polypharmacy showed no clear effect on sarcopenia in humans (residents of nursing homes or inpatients).

    “There is an association between sarcopenia or risk for sarcopenia and polypharmacy or the number of medications in community-dwelling older adults but not among residents of nursing homes or inpatients.”

    Reviewresidents of nursing homes or inpatients

    Sarcopenia and polypharmacy among older adults: A scoping review of the literature

    Archives of gerontology and geriatrics

More on Sarcopenia

Activities of daily living

no changein humans2downin humans1

3 studies
  1. Polypharmacy was not clearly linked with activities of daily living in humans (p = 0.656).

    “or activities of daily living (p = 0.656)”

    Humansn = 164

    Multidimensional Impact of Polypharmacy on Cognitive Function, Depression, Functionality, and Quality of Life in Older Adults: A Cross-Sectional Study

    İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi

  2. Polypharmacy is linked with worse activities of daily living in humans (fully adjusted model) (B = 0.14, p = 0.007).

    “polypharmacy remained independently associated with poorer functional status in fully adjusted models, showing higher K-ADL scores (B = 0.14, p = 0.007)”

    Humansfully adjusted modeln = 9,898

    Associations of polypharmacy with cognitive impairment and functional status among older adults

    Exploration of Medicine

  3. Polypharmacy was not clearly linked with activities of daily living in humans (institutionalized older adults).

    “Polypharmacy was not associated with the functionality of the older adults to perform activities of daily living”

    Humansinstitutionalized older adultsn = 193

    The Prevalence of Polypharmacy and Potentially Inappropriate Medications and Its Relationship with Cognitive Status in Portuguese Institutionalized Older Adults: A Cross-Sectional Study

    International journal of environmental research and public health

Handgrip strength

no changein humans1downin humans1

2 studies
  1. Polypharmacy was not clearly linked with handgrip strength in patients with normal HGS.

    “No significant association was found in patients with normal HGS.”

    Humansin patients with normal HGSn = 300

    Association between Polypharmacy and Handgrip Strength in Older Patients undergoing Convalescent Rehabilitation: A Retrospective Cohort Study

    Annals of geriatric medicine and research

  2. Polypharmacy is linked with lower handgrip strength in humans after adjustment for age, sex, height, arm circumference, and BMI (ptrend<0.001 in men and women).

    “Handgrip strength decreased significantly in both men and women (ptrend<0.001 for both) with increasing medication use after adjustment for age, sex, height, arm circumference, and BMI.”

    Humansafter adjustment for age, sex, height, arm circumference, and BMImale and females

    Association Between Reduced Handgrip Strength and Commonly Prescribed Medications

    medRxivPreprint

Serum drug levels

upin mice1no changein mice1

2 studies
  1. Polypharmacy increases serum drug levels in mice.

    “Polypharmacy altered the hepatic expression of proteins involved in immunity, and in drug, cholesterol, and amino acid metabolism, accompanied by higher serum drug levels than monotherapies.”

    Animalsmales

    Chronic polypharmacy, monotherapy, and deprescribing: Understanding complex effects on the hepatic proteome of aging mice

    Aging cell

  2. Polypharmacy showed no clear effect on serum drug levels in mice (comparison across ages and sexes within polypharmacy-treated animals).

    “Drug levels at steady state were not significantly different between polypharmacy-treated animals of both ages and sexes.”

    Animalscomparison across ages and sexes within polypharmacy-treated animals

    Polypharmacy Results in Functional Impairment in Mice: Novel Insights Into Age and Sex Interactions

    The journals of gerontology. Series A, Biological sciences and medical sciences

More on Serum drug levels

Grip strength

downin humans1downin mice1

2 studies
  1. Polypharmacy is linked with worse grip strength in humans after adjusting for confounding factors (aOR = 2.142, 95 % CI = 1.100-4.171).

    “hyperpolypharmacy (≥ 10 medications) demonstrated associations with weak grip strength (adjusted odds ratio [aOR] = 2.142, 95 % confidence interval [CI] = 1.100-4.171)”

    Humansafter adjusting for confounding factors3-yearn = 1,401

    Effects of multimorbidity and polypharmacy on physical function in community-dwelling older adults: A 3-year prospective cohort study from the SONIC

    Archives of gerontology and geriatrics

  2. Polypharmacy decreases grip strength in mice (greater decline in males than females) (p < .05).

    “Grip strength declined more in males than females (p < .05).”

    Animalsgreater decline in males than females4-6 weeksmales

    Polypharmacy Results in Functional Impairment in Mice: Novel Insights Into Age and Sex Interactions

    The journals of gerontology. Series A, Biological sciences and medical sciences

Gait speed

downin humans2OR 1.248

2 studies
  1. Polypharmacy is linked with worse gait speed in humans (early-stage Alzheimer patients) (OR 1.248 (95% CI 1.145-1.523)).

    “polypharmacy was independently associated with slow UGS [Odds ratio (OR) 1.248 (95%) confidence interval (CI) 1.145-1.523, p = .007]”

    Humansearly-stage Alzheimer patientsn = 134

    The relationship between polypharmacy and physical performance in patients with early-stage Alzheimer's disease

    Current medical research and opinion

  2. Polypharmacy is linked with lower gait speed in humans (cognitively normal outpatients) (β -0.128 [-0.022 to -0.0033]).

    “gait speed had significant negative associations with number of medications and polypharmacy status in the CN group”

    Humanscognitively normal outpatientsn = 431

    Associations Between Polypharmacy and Gait Speed According to Cognitive Impairment Status: Cross-Sectional Study in a Japanese Memory Clinic

    Journal of Alzheimer's disease : JAD

Canagliflozin effect on kidney and cardiovascular outcomes

no changein humans1

1 study
  1. Polypharmacy showed no clear effect on canagliflozin effect on kidney and cardiovascular outcomes in humans.

    “The effect of canagliflozin on kidney and cardiovascular outcomes was consistent irrespective of polypharmacy status”

    Human trialn = 4,401

    Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

All-cause hospitalization

upin humans1

1 study
  1. Polypharmacy increases all-cause hospitalization in humans.

    “Incidence of all-cause hospitalization, and heart failure hospitalization or cardiovascular death increased with higher medication burden”

    Human trialn = 4,401

    Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

All 60

What is polypharmacy linked with?

174

Studies link polypharmacy with 174 measures, most often mortality (55 studies), frailty (54) and falls (10).

Mortality

upin humans52downin humans2no changein humans1HR 1.03–21.4

55 studies
  1. Polypharmacy is linked with a higher risk of mortality in humans (aOR 2.12).

    “polypharmacy was independently associated with higher odds of recurrent all-cause ED visits (aOR 2.41), hospitalizations (aOR 2.18), pneumonia-related ED visits (aOR 1.97), pneumonia hospitalizations (aOR 2.63), and mortality (aOR 2.12).”

    Humansn = 192

    Polypharmacy and Healthcare Utilization Outcomes in Older Adults: A Retrospective Study

    International Journal of Pharmaceutical Quality Assurance

  2. Polypharmacy is linked with a higher risk of mortality in humans (fully adjusted models including all higher-risk medication exposures) (HR 1.38; 95% CI 1.26-1.51).

    “only polypharmacy remained significantly associated with increased mortality (hazard ratio [HR] 1.38; 95% CI 1.26-1.51).”

    Humansfully adjusted models including all higher-risk medication exposuresn = 7,828

    Five or more drugs linked to higher death risk in older adults

    Journal of the American Geriatrics Society

  3. Polypharmacy is linked with a higher risk of mortality in humans (dose-response per each additional medication) (HR: 1.05, 95% CI: 1.03-1.06).

    “Dose-response meta-analyses showed a monotonic increase in risk with each additional medication for mortality (HR: 1.05, 95% CI: 1.03-1.06, p < .001)”

    Humansdose-response per each additional medication

    Global prevalence, trends, and dose-response associations of polypharmacy in older adults

    The journals of gerontology. Series A, Biological sciences and medical sciences

  4. Polypharmacy is linked with a higher risk of mortality in humans (geriatric staircase falls).

    “After adjusting for covariates, polypharmacy remained an independent risk factor for mortality (p = 0.042).”

    Humansgeriatric staircase fallsn = 529

    Retrospective analysis of mortality and the influence of polypharmacy in geriatric staircase falls

    BMC geriatrics

  5. Polypharmacy is associated with mortality in humans after hip fracture surgery (HR 3.65, 95% CI 2.73-4.88; fully adjusted HR 3.12).

    “Crude hazard ratios for 5-year mortality were 3.65 (95% CI 2.73-4.88) for patients taking 5-9 drugs and 4.51 (95% CI 3.26-6.24) for those taking ≥ 10 drugs”

    Humansafter hip fracture surgery5-9 drugs5 yearsn = 644

    Real-world evidence of the impact of polypharmacy on mortality and recovery after hip fracture in elderly patients

    Scientific reports

  6. Polypharmacy is linked with a higher risk of mortality in humans (Alzheimer's disease confirmed by CSF biomarkers (A+ T+)) (HR 1.06, 95% CI 1.01-1.11).

    “In adjusted models, mortality was associated with the number of drugs [hazard ratio (HR) 1.06, 95% confidence interval (CI) 1.01-1.11]”

    HumansAlzheimer's disease confirmed by CSF biomarkers (A+ T+)mean follow-up of 7.3 yearsn = 440

    Assessment of medication-related risks for mortality prediction in Alzheimer's disease

    Maturitas

  7. Polypharmacy is associated with mortality in humans (acute kidney injury initiating intermittent hemodialysis during hospitalization).

    “Significant associations were observed between mortality and polypharmacy, sepsis, and multiple comorbidities.”

    Humansacute kidney injury initiating intermittent hemodialysis during hospitalization50% mensn = 48

    Factors associated with mortality in patients older than 60 years with acute kidney injury undergoing initial intermittent hemodialysis

    Revista sanitaria de investigación.

  8. Polypharmacy is associated with mortality in humans (critically ill patients receiving mechanical ventilation) (HR 1.17, 95% CI 0.85–1.60).

    “patients with polypharmacy at admission were not independently associated with all-cause mortality (hazard ratio [HR]: 1.17, 95% confidence interval [CI]: 0.85–1.60).”

    Humanscritically ill patients receiving mechanical ventilationn = 533

    Association between polypharmacy at the emergency department and long-term mortality in critically ill older patients receiving mechanical ventilation: a single-center retrospective cohort study

    BMC emergency medicine

  9. Polypharmacy is associated with mortality in humans (undergoing rehabilitation after fracture or elective orthopedic surgery) (HR 2.23, 95% CI 1.24-4.10, p = 0.007).

    “polypharmacy was independently linked to a higher risk of mortality, falls and hospitalizations (HR 2.23, 95% CI 1.24-4.10, p = 0.007).”

    Humansundergoing rehabilitation after fracture or elective orthopedic surgeryn = 205

    Polypharmacy and Dynapenia in Older Adults Undergoing Rehabilitation After Fracture or Elective Orthopedic Surgery

    Medicina (Kaunas, Lithuania)

  10. Polypharmacy is linked with a higher risk of mortality in humans (OR 3.17, 95% CI 1.19-8.44).

    “Polypharmacy was significantly associated with higher hospitalization risk (OR, 1.52; 95% CI, 1.28-1.81) and mortality (OR, 3.17; 95% CI, 1.19-8.44).”

    Humans

    Healthcare burden and clinical outcomes of polypharmacy in older adults: a population-based cohort study in South Korea

    Archives of public health = Archives belges de sante publique

All 55

Frailty

upin humans51mixedin humans2upin mice1+63% frail participants had polypharmacyOR 1.432–8.22

54 studies
  1. Polypharmacy is associated with frailty in humans (multivariable logistic regression).

    “Multivariable logistic regression revealed that living with family, polypharmacy, malnourishment/risk of malnutrition and IADL dependency were independently associated with frailty.”

    Humansmultivariable logistic regressionn = 210

    Overlap and Determinants of Sarcopenia and Frailty among Rural and Urban Community-Dwelling Older Adults in Doiwala Block, Dehradun, Uttarakhand: A Cross-Sectional Study

    Indian Journal of Community Health

  2. Polypharmacy is associated with frailty in humans (stage III-IV cancer; multivariable analysis) (OR 8.22, 95% CI 2.13–31.64).

    “In the multivariable analysis, polypharmacy was strongly associated with frailty (OR: 8.22, 95% CI: 2.13–31.64, p=0.002).”

    Humansstage III-IV cancer; multivariable analysis≥5 concurrent medicationsn = 200

    Polypharmacy and frailty in geriatric oncology patients with advanced cancer: A prospective observational study

    Health Sciences Quarterly

  3. Polypharmacy is associated with frailty in humans (elderly IBD outpatients).

    “Frailty was independently associated with polypharmacy and CIRS-G ≥ 3 on multivariate analysis of the four scales.”

    Humanselderly IBD outpatientsn = 612

    The Prevalence of Frailty in Elderly Inflammatory Bowel Disease Patients Varies Depending on the Scale Used

    Alimentary pharmacology & therapeutics

  4. Polypharmacy is associated with frailty in humans (hospitalized older adults with multimorbidity in Northwest Ethiopia).

    “Frailty was significantly associated with PIM, PPO, female gender, use of polypharmacy, and dependency in activities of daily living (ADL) in multivariable analysis.”

    Humanshospitalized older adults with multimorbidity in Northwest Ethiopian = 407

    Association of potentially inappropriate prescribing with frailty among older adults with multimorbidity in Northwest Ethiopia

    npj aging

  5. Polypharmacy is associated with frailty in humans among maintenance hemodialysis patients, frail versus non-frail.

    “more frequent polypharmacy compared with non-frail individuals”

    Humansamong maintenance hemodialysis patients, frail versus non-frailn = 136

    Prevalence of Frailty and Associated Risk Factors in Geriatric Maintenance Hemodialysis Patients: A Cross-Sectional Study

    Hitit Medical Journal

  6. Polypharmacy is associated with frailty in humans (Institutionalized older adults) (62.5 % of frail participants had polypharmacy).

    “A high frequency of frailty was detected in older adults aged 80 years and older, of female sex, with greater comorbidity and the presence of polypharmacy.”

    HumansInstitutionalized older adultsn = 17

    Detection of frailty in institutionalized older adults

    Revista sanitaria de investigación.

  7. Polypharmacy is associated with frailty in humans (Older Vietnamese inpatients; univariate analysis) (Polypharmacy prevalence: 53.6% in robust, 75.3% in prefrail, and 80.0% in frail patients; p=0.005).

    “Polypharmacy is highly prevalent among older Vietnamese inpatients and is strongly associated with frailty in univariate analysis”

    HumansOlder Vietnamese inpatients; univariate analysis≥ 5 concurrent medications97.3% malesn = 188

    Polypharmacy and frailty among older inpatients in Vietnam

    Journal of 108 - Clinical Medicine and Phamarcy

  8. Polypharmacy is associated with frailty in humans.

    “A higher number of chronic medications was associated with higher FRAIL scores, lower IPAQ scores and more frequent healthcare utilization”

    Humansn = 104

    Polypharmacy and hyperpolypharmacy in elderly (≥ 65 years) pacemaker recipients: Prevalence and association with frailty, physical activity, adherence, and healthcare utilization in a prospective single-center study

    International journal of clinical pharmacology and therapeutics

  9. Polypharmacy is associated with frailty in humans (41.07% vs comparison).

    “The prevalence of frailty was significantly higher in the polypharmacy group, affecting 41.07% of the study participants.”

    Humansn = 488

    Association Between Polypharmacy and Frailty in Elderly Patients Receiving Care at a Public Hospital in South India

    Biomedical Sciences and Clinical Medicine

  10. Polypharmacy is associated with frailty in humans (β = 0.198, P < 0.001).

    “Frailty score was significantly associated with ADL (β = -0.296, P < 0.001), polypharmacy (β = 0.198, P < 0.001)”

    Humansn = 764

    Multifactorial analysis of risk factors for frailty and cognitive frailty among hospitalized patients

    BMC geriatrics

All 54

Falls

upin humans9no changein humans1OR 0.65–9.06

10 studies
  1. Polypharmacy is associated with falls in humans (receiving care at a university clinic).

    “The occurrence of falls was associated with polypharmacy (p=0.024)”

    Humansreceiving care at a university clinicn = 21

    Polypharmacy and functional impairment as factors associated with the occurrence of falls in older adults

    Veredas do Direito Direito Ambiental e Desenvolvimento Sustentável

  2. Polypharmacy is associated with falls in humans (OR 0.65, 95% CI 0.40-1.05).

    “polypharmacy (OR 0.65, 95% CI 0.40-1.05).”

    Humansn = 626

    Anticholinergic Burden, Falls, and the Concept of Appropriate Polypharmacy in Indonesian Geriatric Clinics: A Multicentre Observational Study

    Acta medica Indonesiana

  3. Polypharmacy is linked with a higher risk of falls in humans (OR = 2.31, 95% CI = 1.06-5.04).

    “Polypharmacy users had 2.3 times higher odds of reporting two or more falls in the previous 12 months (odds ratio [OR] = 2.31, 95% CI = 1.06-5.04).”

    Humansprevious 12 monthsn = 468

    Polypharmacy and Associated Health Outcomes in the PARI-HD Study

    Journal of Alzheimer's disease : JAD

  4. Polypharmacy is linked with a higher risk of falls in older persons with HIV.

    “taking a higher number of non-ARV medications significantly increased the odds of having a fall.”

    Humansin older persons with HIV

    The Impact of Number of Medications on Falls in Aging Persons with Human Immunodeficiency Virus

    Life (Basel, Switzerland)

  5. Polypharmacy is linked with a higher risk of falls in humans (adjusted for age, sex, CCI, CDR, mobility) (0.84/pyrs vs 1.13/pyrs vs 1.84/pyrs).

    “Falls increased significantly with the number of medications used.”

    Humansadjusted for age, sex, CCI, CDR, mobility12 monthsn = 532

    Association of medication use with falls and mortality among long-term care residents: a longitudinal cohort study

    BMC geriatrics

  6. Polypharmacy is linked with a higher risk of falls in humans (adjusted for covariates) (OR 9.06, 95 % CI [2.56, 32.04], p = 0.012).

    “Polypharmacy was associated with a history of falls (OR 9.06, 95 % CI [2.56, 32.04], p = 0.012)”

    Humansadjusted for covariatesn = 206

    Number of medications and polypharmacy are associated with risk of fall in Saudi community-dwelling adults

    Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

  7. Polypharmacy predicts falls in humans.

    “Medication number also predicted fall episodes (p = 0.02) and frailty progression (p = 0.002).”

    Humans2 yearsn = 573

    Polypharmacy Predicts Onset and Transition of Frailty, Malnutrition, and Adverse Outcomes in Peritoneal Dialysis Patient

    The journal of nutrition, health & aging

  8. Polypharmacy is linked with a higher risk of falls in humans (hypertensive older adults) (adjusted OR 2.513, 95% CI 1.339, 4.718).

    “Polypharmacy (adjusted OR 2.513, 95% CI 1.339, 4.718) and diuretics (adjusted OR 2.803, 95% CI 1.418, 5.544) were associated with an increased risk of falls.”

    Humanshypertensive older adults

    Older Adults with Hypertension: Prevalence of Falls and Their Associated Factors

    International journal of environmental research and public health

  9. Polypharmacy is linked with a higher risk of falls in humans (OR 1.43, 95% CI 1.01-2.03).

    “inpatients with polypharmacy had an increased risk of falls (OR 1.37, 95%CI 1.17-1.56 for the cross-sectional association; OR 1.43, 95% CI 1.01-2.03 for the longitudinal association, respectively)”

    Humansfive medications or more1-yearn = 9,062

    Association of polypharmacy with falls among older Chinese inpatients: A nationwide cohort study

    Geriatrics & gerontology international

  10. Polypharmacy is associated with falls in humans.

    “Polypharmacy and comorbid conditions increases the risk of falls.”

    Humansn = 537

    The syndrome of falls in the elderly

    Advances in gerontology = Uspekhi gerontologii

Hospitalization

upin humans7HR 1.09

7 studies
  1. Polypharmacy is linked with a higher risk of hospitalization in humans (compared to cardiometabolic medications dominant group) (HR 1.09, 95% CI 1.09-1.10).

    “all-cause hospitalisation (1·09 [1·09-1·10] and1·08 [1·07-1·09])”

    Humanscompared to cardiometabolic medications dominant group6-yearn = 787,072

    Multi-trajectories of polypharmacy composition and clinical outcomes by frailty status: a longitudinal cohort study

    Age and ageing

  2. Polypharmacy is linked with a higher risk of hospitalization in humans (OR 1.52, 95% CI 1.28-1.81).

    “Polypharmacy was significantly associated with higher hospitalization risk (OR, 1.52; 95% CI, 1.28-1.81)”

    Humans

    Healthcare burden and clinical outcomes of polypharmacy in older adults: a population-based cohort study in South Korea

    Archives of public health = Archives belges de sante publique

  3. Polypharmacy is linked with a higher risk of hospitalization in humans (non-chronic polypharmacy therapy (≤2 DDDs) vs. not on polypharmacy) (+39% (95% CI 28%-51%)).

    “hospitalization [39% (28%-51%) and 61% (49%-75%), respectively]”

    Humansnon-chronic polypharmacy therapy (≤2 DDDs) vs. not on polypharmacyn = 5,631

    Polypharmacy in Older Adults: The Hazard of Hospitalization and Mortality is Mediated by Potentially Inappropriate Prescriptions, Findings From the Moli-sani Study

    International journal of public health

  4. Polypharmacy is linked with a higher risk of hospitalization in humans (aOR 1.32, 95% CI 1.31-1.33).

    “In patients who exhibited polypharmacy for more than 180 days, the adjusted odds ratio of adverse outcomes was 1.32 (95% confidence interval [CI], 1.31-1.33) for hospitalization”

    Humans>180 days

    The association between continuous polypharmacy and hospitalization, emergency department visits, and death in older adults: a nationwide large cohort study

    Frontiers in pharmacology

  5. Polypharmacy predicts hospitalization in humans.

    “Being female, polypharmacy, the presence of at least one comorbidity, cancer, and chronic renal failure were found to be independent predictors of hospitalization”

    Humans

    Effect of Comorbid Diseases on Hospitalization and In-Hospital Mortality of Elderly Patients Who Reapplied to the Emergency Department Within 72 Hours

    Cureus

  6. Polypharmacy is linked with a higher risk of hospitalization in humans (colorectal cancer survivors).

    “The PP and excess PP groups showed increased risk of all-cause mortality, hospitalization, and ER visit compared with the low PP group”

    Humanscolorectal cancer survivorsn = 55,228

    Association of polypharmacy with all-cause mortality and adverse events among elderly colorectal cancer survivors

    Cancer

  7. Polypharmacy is associated with hospitalization in humans (50% increased, RR=1.50, 95%CI (1.18,1.89)).

    “Eight studies showed an 50% increased hospitalization rate for polypharmacy in the older adults [RR=1.50, 95%CI (1.18,1.89), P<0.05].”

    Review

    Association between polypharmacy and mortality in the older adults: A systematic review and meta-analysis

    Archives of gerontology and geriatrics

Sarcopenia

upin humans6OR 2.192–4.489

6 studies
  1. Polypharmacy is associated with sarcopenia in humans (newly diagnosed, untreated hypothyroidism) (OR 2.192, 95% CI 1.119–4.294).

    “age ≥75 years (OR=2.309,95%CI 1.366-3.905) and polypharmacy (OR=2.192,95%CI 1.119-4.294) were risk factors”

    Humansnewly diagnosed, untreated hypothyroidismn = 147

    Analysis of prevalence status and risk factors of sarcopenia in elderly patients with hypothyroidism

    Chinese Journal of Multiple Organ Diseases in the Elderly

  2. Polypharmacy is associated with sarcopenia in humans (community-dwelling older adults) (55% vs. 16%, p < 0.001).

    “Compared with the non-sarcopenia group, the sarcopenia group showed a higher prevalence of polypharmacy (≥5 medications) (55% vs. 16%; p < 0.001)”

    Humanscommunity-dwelling older adultsn = 182

    Exploring the Association of Polypharmacy and Depressive Symptoms with Sarcopenia in Older Adults

    Journal of clinical medicine

  3. Polypharmacy is linked with a higher risk of sarcopenia in humans (OR 4.489 (95% CI 1.315-15.320)).

    “polypharmacy (OR, 4.489; 95% CI, 1.315-15.320)”

    Humansmultivariate logistic regression adjusted for age, gender, education and confounders in MCI and early-stage ADn = 205

    Association Between Appetite and Sarcopenia in Patients With Mild Cognitive Impairment and Early-Stage Alzheimer's Disease: A Case-Control Study

    Frontiers in nutrition

  4. Polypharmacy is associated with sarcopenia in humans (older inpatients) (OR 2.36, 95% CI 1.28–4.34).

    “polypharmacy (OR 2.36, 95% CI 1.28-4.34)”

    Humansolder inpatientsn = 407

    Prevalence of sarcopenia and associated factors in hospitalised older patients: A cross-sectional study

    Australasian journal on ageing

  5. Polypharmacy is associated with sarcopenia in humans (adjusted for sex, age, comorbid conditions and physical activity) (OR 2.24, 95% CI 1.33-3.75).

    “polypharmacy was consistently associated with a significantly increased likelihood of sarcopenia (odds ratio = 2.24, 95% confidence interval [CI] = 1.33-3.75)”

    Humansadjusted for sex, age, comorbid conditions and physical activity

    Polypharmacy as a Risk Factor for Clinically Relevant Sarcopenia: Results From the Berlin Aging Study II

    The journals of gerontology. Series A, Biological sciences and medical sciences

  6. Polypharmacy is associated with sarcopenia in humans (community-dwelling older adults).

    “Sarcopenia or risk for sarcopenia are associated with polypharmacy or the number of medications in community-dwelling older adults”

    Reviewcommunity-dwelling older adults

    Sarcopenia and polypharmacy among older adults: A scoping review of the literature

    Archives of gerontology and geriatrics

More on Sarcopenia

Physical function

downin humans4mixedin humans1OR 2.4

5 studies
  1. Polypharmacy is associated with physical function in humans.

    “Female gender, polypharmacy, and smoking were additional variables significantly associated with degraded SMAF and/or ADL/IADL.”

    Humansn = 753

    Risk factors of frailty and functional disability in community-dwelling older adults: a cross-sectional analysis of the FREEDOM-LNA cohort study

    BMC geriatrics

  2. Polypharmacy is associated with physical function in humans (adjusted for age, sex, BMI, and comorbidities (Model 2)) (OR 2.4, 95% CI 1.2-4.8).

    “polypharmacy was independently associated with poor SPPB (Odds Ratio (OR)=2.5; 95% Confidence Interval (CI)=1.3-4.7 and OR=2.4; 95% CI=1.2-4.8 for Model 1 and 2, respectively)”

    Humansadjusted for age, sex, BMI, and comorbidities (Model 2)n = 392

    Associations between polypharmacy and physical performance measures in older adults

    Archives of gerontology and geriatrics

  3. Polypharmacy is associated with physical function in humans.

    “The findings indicated associations between multiple medication use, falls, and changes in physical performance, particularly gait and mobility.”

    Review

    Polifarmácia e o risco de queda no idoso: revisão de literatura

    Revista fisio&terapia.

  4. Polypharmacy is associated with physical function in humans.

    “polypharmacy is associated with increased adverse reactions, drug interactions, recurrent hospitalizations, functional impairment, frailty, and mortality.”

    Review

    Effect of polypharmacy on quality of life and life expectancy in older adults

    Brazilian Journal of Implantology and Health Sciences

  5. Polypharmacy is associated with physical function in humans (critical illness).

    “Polypharmacy is associated with adverse drug events, functional decline, and mortality.”

    Reviewcritical illness

    Multimorbidity, polypharmacy and frailty in critically ill older adults

    European geriatric medicine

Multimorbidity

upin humans5OR 2.31

5 studies
  1. Polypharmacy is associated with multimorbidity in humans (Adjusted association in adults attending a rural primary care hospital) (Adjusted OR 2.31, 95% CI 0.92–5.81; p=0.076; not statistically significant).

    “Polypharmacy was associated with increased odds of multimorbidity, although the adjusted association was not statistically significant”

    HumansAdjusted association in adults attending a rural primary care hospitaln = 304

    Multimorbidity, polypharmacy and the clinical profile of adults attending a rural primary care hospital: a retrospective cross-sectional study

    International Journal of Community Medicine and Public Health

  2. Polypharmacy is associated with multimorbidity in individuals with polypharmacy.

    “Burden increased with age and was higher among individuals with chronic conditions”

    Humansin individuals with polypharmacy1 yearn = 33,534

    Polypharmacy, multimorbidity, and socioeconomic inequalities in a Spanish region: a population-based cross-sectional study

    Frontiers in public health

  3. Polypharmacy predicts multimorbidity in humans (aOR = 1.82, 95% CI: 1.45–2.28, p < 0.001).

    “high medication burden was a potent predictor of multimorbidity (Adjusted Odds Ratio (aOR) = 1.82; 95% CI: 1.45–2.28; p < 0.001).”

    Humans

    Medication Burden as a Determinant of Clinical Complexity and Multimorbidity: A Population-Based Analysis among the Elderly in Eastern India

    International Journal of Drug Delivery Technology

  4. Multimorbidity predicts polypharmacy in humans (AOR 6.303, Cl 4.009-9.911, p < 0.0001).

    “three variables emerged as influential predictors of polypharmacy namely, 3 or more diseases (AOR 6.303, Cl 4.009-9.911, p < 0.0001)”

    Humansn = 488

    Association Between Polypharmacy and Frailty in Elderly Patients Receiving Care at a Public Hospital in South India

    Biomedical Sciences and Clinical Medicine

  5. Polypharmacy is associated with multimorbidity in humans (elderly of an educational program) (P < .05).

    “being higher among elderly individuals self-reporting their health as regular or bad/or very bad, having systemic arterial hypertension, diabetes mellitus, dyslipidaemia, hypothyroidism, overweight/obesity, and depression, including polypharmacy (P < .05)”

    Humanselderly of an educational programn = 150

    Multimorbidity in the elderly of an educational program in Brazilian capital: A cross-sectional study

    Medicine

More on Multimorbidity

Handgrip strength

downin humans4

4 studies
  1. Polypharmacy is associated with handgrip strength in humans (19kg [SD 10.2], p=0.020).

    “weaker HGS (19kg [SD 10.2], p=0.020)”

    Humansn = 74

    Differential factors associated with muscle quantity and quality in older adults

    Revista espanola de geriatria y gerontologia

  2. Polypharmacy is associated with handgrip strength in the low-HGS group (B=-0.064, approximately 6% lower improvement).

    “In the low-HGS group, polypharmacy was independently associated with poorer HGS recovery (B=-0.064), corresponding to approximately 6% lower improvement.”

    Humansin the low-HGS groupn = 1,350

    Association between Polypharmacy and Handgrip Strength in Older Patients undergoing Convalescent Rehabilitation: A Retrospective Cohort Study

    Annals of geriatric medicine and research

  3. Polypharmacy is associated with handgrip strength in humans (sex- and age-adjusted multivariable model (adjusted R2 = 0.442)) (β = -4.20, p = 0.002).

    “polypharmacy (β = -4.20, p = 0.002), and slower gait speed (β = 4.12, p = 0.010) were associated with reduced handgrip strength”

    Humanssex- and age-adjusted multivariable model (adjusted R2 = 0.442)

    High Prevalence of Probable Sarcopenia and Its Associations with Nutrition, Cognitive, and Physical Function in Hospitalized Patients with Alzheimer's Clinical Syndrome: A Cross-Sectional Study

    Nutrients

  4. Polypharmacy is associated with handgrip strength in humans (convalescent rehabilitation after stroke) (β = -0.070, p = 0.022).

    “HG (β = -0.070, p = 0.022)”

    Humansconvalescent rehabilitation after stroken = 361

    Association of polypharmacy at hospital discharge with nutritional intake, muscle strength, and activities of daily living among older patients undergoing convalescent rehabilitation after stroke

    Japanese journal of comprehensive rehabilitation science

Cognitive function

upin humans2downin humans2

4 studies
  1. Polypharmacy is associated with cognitive function in humans (unadjusted analysis) (p < 0.05).

    “Polypharmacy was associated with better functional and cognitive scores in unadjusted analyses (p < 0.05), although these associations were not independent after adjustment.”

    Humansunadjusted analysisn = 848

    Prevalence and determinants of polypharmacy and its association with cognitive and functional performance in community-dwelling older adults: A population-based study

    Journal of Alzheimer's disease : JAD

  2. Polypharmacy is associated with cognitive function in humans.

    “reductions from moderate or high to lower polypharmacy levels yielded cognitive improvements - particularly in motor function - in both PWH and VS-PWH populations.”

    HumansReduction from moderate or high to lower polypharmacy in people with HIV, including virally suppressed people

    Longitudinal effects of polypharmacy on cognitive function in people with HIV

    AIDS (London, England)

  3. Polypharmacy predicts cognitive function in humans (taking ≥9 medications at discharge) (β = -0.466, P = .003).

    “taking ≥9 medications at discharge was an independent predictor of lower cognitive FIM scores (β = -0.466, P = .003).”

    Humanstaking ≥9 medications at dischargen = 86

    Relationship between polypharmacy and activities of daily living or in-hospital falls in elderly patients hospitalized for proximal femoral fracture: A retrospective cohort study

    Medicine

  4. Polypharmacy is associated with cognitive function in humans (institutionalized older adults) (p = 0.039).

    “The older adults with lower scores on the Mini Mental State Examination (MMSE) took more drugs (p = 0.039)”

    Humansinstitutionalized older adultsn = 193

    The Prevalence of Polypharmacy and Potentially Inappropriate Medications and Its Relationship with Cognitive Status in Portuguese Institutionalized Older Adults: A Cross-Sectional Study

    International journal of environmental research and public health

Functional status

downin humans3upin humans1

4 studies
  1. Polypharmacy is associated with functional status in humans (unadjusted analysis) (p < 0.05).

    “Polypharmacy was associated with better functional and cognitive scores in unadjusted analyses (p < 0.05), although these associations were not independent after adjustment.”

    Humansunadjusted analysisn = 848

    Prevalence and determinants of polypharmacy and its association with cognitive and functional performance in community-dwelling older adults: A population-based study

    Journal of Alzheimer's disease : JAD

  2. Polypharmacy is associated with functional status in humans (geriatric healthcare system) (r = -0.11, p<0.05).

    “a negative correlation with functional status (r = -0.11, p<0.05)”

    Humansgeriatric healthcare systemn = 600

    The Complexity of Aging: Managing Multimorbidity in Geriatrics

    Cureus

  3. Polypharmacy is associated with functional status in humans (outpatient medical oncology patients with cancer).

    “Polypharmacy was strongly associated with decreased functional status.”

    Humansoutpatient medical oncology patients with cancern = 274

    Use of an Abbreviated Geriatric Screening Tool in the Assessment of Older Cancer Patients' Functional Status, Dependency, and Comorbidities: Cross-Sectional Audit and Observations From a Regional Cancer Center in Australia

    JMIR cancer

  4. Polypharmacy is associated with functional status in humans (Polypharmacy and excessive polypharmacy groups).

    “Proportion of subjects with a decline in cognitive status, functional status and mobility increased in polypharmacy and excessive polypharmacy group.”

    HumansPolypharmacy and excessive polypharmacy groups5–9 or ≥10 medicationsn = 88,878

    How healthy is community-dwelling elderly population? Results from Southern Italy

    Translational medicine @ UniSa

All 174

Has polypharmacy been tested in people?

0 of 1 about aging

Yes: 5 trials and 395 observational studies in people have been published, and 1 trial is registered.

In trials

Trial sponsors

Funding

16 grants since 2017

National Institute on Aging$3.3MJapan Society for the Promotion of Science¥16.5MGouvernement du Canada | Canadian Institutes of Health ResearchCA$164K

Contains public sector information licensed under the Open Government Licence v3.0.

Latest

Dec 2025: 10Jan 2026: 17Feb 2026: 12Mar 2026: 7Apr 2026: 14May 2026: 14Jun 2026: 12Jul 2026: 21Aug 2026: 4Sep 2026: 7Oct 2026: 20Nov 2026: 4142 papers in 12 months
Breast

Some older women may gain little from breast cancer hormone therapy

An observational study found no significant survival differences with hormone therapy among women with stage I breast cancer who were older, had other illnesses or took…An observational study found no significant survival differences with hormone therapy among women with stage I breast cancer who were older, had other illnesses or took multiple medicines.

Cohort studyInterventions

See all 470 papers on polypharmacy